VIDEO: Expert highlights data on treatments for KRAS G12C non-small cell lung cancer
Click Here to Manage Email Alerts
In this video, Jia Luo, MD, discusses two presentations from International Association for the Study of Lung Cancer World Conference on Lung Cancer investigating treatments for KRAS G12C lung cancer.
CodeBreaK 100/101 reported the safety and efficacy of a sotorasib (Lumakras, Amgen) and pembrolizumab (Keytruda, Merck) combination treatment when compared with atezolizumab (Tecentriq, Genentech) in patients with advanced KRAS G12C non-small cell lung cancer, according to Luo, thoracic medical oncologist and cancer researcher with Dana-Farber and Harvard Medical School.
“These early reports suggest that, maybe, in combination with immunotherapy, we should consider additive effects of liver function abnormalities and perhaps lower doses of the G12C inhibitor may be needed from here on out,” she said.
The second study, a phase two trial, looked at a combination of sotorasib with the SHP2 inhibitor RMC-4630 for the treatment of patients with advanced KRAS G12C NSCLC who previously failed standard therapies.
References:
- Johnson ML. RMC-4630, a SHP2 Inhibitor, in Combination with Sotorasib for Advanced KRASG12C NSCLC After Failure of Prior Standard Therapies: A Phase 2 Trial. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
- Li BT. CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC. Presented at: International Association for the Study of Lung Cancer World Conference on Lung Cancer (hybrid meeting); Aug. 6-9, 2022; Vienna.
Collapse
Healio Interviews
Click Here to Manage Email Alerts